next generation glp 1 drugs The of GLP-1 weight loss Obesity plus': What's next for

He has also received grants from Medical Research Council, European Union, JPND, Alzheimers Research, UK, Alzheimers Drug Discovery Foundation, Alzheimers Society, UK, Alzheimers Association, US, Medical P.E

However, further studies have revealed that -cells in the pancreatic islets, and neurons in the nucleus of the solitary tract are also able to produce GLP-1

Pretreatment with GLP-1(2836) reduces infarct size in mice and provides direct GLP-1Rindependent cardioprotection in isolated mouse hearts

Global Glp 1 Receptor Agonists Obesity Drugs Market Market Size in USD Billion GLP-1 Receptor Agonists Obesity Drugs Market Size The global GLP-1 receptor agonists obesity drugs market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 33.12 billion by 2032 , at a CAGR of 16.21% during the forecast period The market growth is primarily driven by the increasing need for secure, transparent, and tamper-proof systems to manage sensitive healthcare data, billing processes, and patient records across diverse stakeholders In addition, the rising adoption of blockchain technology by healthcare providers, insurers, and pharmaceutical companies to streamline operations, enhance data integrity, and mitigate fraud is propelling market expansion

Wollenhaupt-Aguiar B, Kapczinski F, Pfaffenseller B

Disclaimer: This article is written with the help of generative tools so beware of hallucinations